Monthly exports of pharmaceutical products have returned to the $700 million mark in half a year, but the deficit is snowballing as imports soar.According to the report from the Korea International Trade Association (KITA), monthly exports of medicinal and pharmaceutical products (SITC54) in Septemb

Exports of diagnostic regents have returned to the $119 million mark. However, the decrease was even greater compared to the same period last year.According to the data from the Korea Customs Service, exports of diagnostic reagents (HS3822) plunged 31.6% YoY to $195.75 million in September.Exports o

In the third quarter, the number of the patent announcement by pharmaceutical and bio companies decreased significantly.According to Newsmp’s tally of patent disclosures in the third quarter through the DART (Disclaimer of Liability & Use/Accuracy of Information), patent disclosures in all industrie

The National Pension Service of Korea (NPS) has built a 5% stake in SK Bioscience and ST Pharm in the third quarter.On the 6th, the NPS announced the ‘5% rule’ (as of September 30) on 7 pharmaceutical and bio companies, including SK Bioscience, ST Pharm, Pharma Research Products, Pharma Research Pro

While pharmaceutical stocks had their worst time in the third quarter, they also struggled with the market capitalization rankings.Newsmp collected data of Q3 market cap rankings of 59 pharmaceutical-related stocks (including preferred stocks) out of 938 listed stocks in the securities market (as of

The KOSPI pharmaceutical stocks, which had been burning for August and relieving the slump of the first half, cooled down in the cold wind of fall.The pharmaceuticals index, which started at 18,000 in August and exceeded 21,000 points, began at 21,000 in September and eventually returned to 18,000 p

Korea’s exports of pharmaceutical products to Germany have increased significantly, exceeding $1.5 billion for 8 months.On the other hand, as imports from Belgium rose sharply, Korea became the second-largest trade deficit country in pharmaceutical products after the United States.According to the d

Trading value for shorting in the pharmaceutical sector in KOSPI exceeded 3 trillion won for a total of 99 trading days until 24 September after the partial resumption of short selling on 3 May.During the same period, the total short selling value in the KOSPI market was KRW 43.1888 trillion, accoun

After the COVID-19 pandemic, the trade deficit has decreased significantly as drug exports increased sharply, but in recent months, the deficit widened again due to vaccine imports.According to the data from the Korea International Trade Association, exports of Medicinal and pharmaceutical products

Korea’s exports of diagnostic reagents (HS3822) recorded 17 months of trade balance surplus in a row. However, the monthly exports and surplus decreased slightly from the same period last year.Exports of diagnostic reagents amounted to $76.47 million in August, exceeding $150 million for the second

Among the listed corporation whose closing account is at the end of December in the first half, Seegene ranked in the top 100 in operating profit with three major bio companies.Based on FnGuide’s data, only four of 149 pharmaceutical manufactures recorded more than KRW 100 billion in half-year opera

In August, pharmaceutical stocks regained vitality and entered the top ranks in trading volume and value.In particular, 10 out of 45 components of the pharmaceutical industry index ranked in the top 100 among more than 900 listed stocks on Korea Stock Exchange (KSE).Among them, SK Bioscience, which

Foreign investors who distanced from Korean pharmaceutical and bio stocks this year are returning in August.According to the Korea Exchange, foreign investors’ purchases of 29 stocks, more than half of the 45 pharmaceutical industry indexes in the securities market, exceeded sales in August.The comb

As of the end of the first half, it was found that 30 listed pharmaceutical companies (based on the company that announces its final results for the year ended December) had more than KRW 100 billion in retained earnings. On the other hand, six pharmaceutical companies’ losses exceeded KRW 10 billio

In the midst of the fourth wave of COVID-19, retail sales of pharmaceutical products are increasing sharply.In July, retail sales of pharmaceutical products exceeded 2.0765 trillion won for the third consecutive month, and broke the all-time high of 2.0739 trillion won in a month, according to data

While the number of patients with urolithiasis has been increasing in South Korea, it has been confirmed that the number is exceptionally high in August every year.Urolithiasis is a disease in which urinary stones are formed in the urinary tract and hinder the flow of urine. Severe pain or urinary t

Major top pharmaceutical companies left improved performance in the second quarter, but the securities firms lowered their target stock prices.Most of the top pharmaceutical companies have announced preliminary operating income since the end of July.While the earning announcements of leading pharmac

Exports of diagnostic reagents have recovered as the global spread of COVID-19 has intensified worldwide.According to the Korea Customs Service, the monthly exports of diagnostic reagents (HS3822) in July were $197.52 million, up 44.7% YoY.During the same period, imports of diagnostic reagents also

Biktarvy (Gilead Sciences) continues to dominate the HIV treatment market.According to Gilead Sciences’ semi-annual report, Biktarvy’s sales jumped 24.3% YoY to more than 2.3 trillion won, and its half-year sales soared to 4.4 trillion won (as of August 11th).Gilead Sciences’ sales of HIV drugs are

The Spinal Muscular Atrophy (SMA) treatment market is changing.With the advent of Evrysdi (Roche), a change is taking place in the competition between Spinraza (Biogen), which is administered every four months via spinal infusion, and Zolgensma (Novartis), one-time gene therapy.According to the repo